• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects

  NCT06448273

  Unknown statusInterventionalPhase 1Updated Aug 12, 2024
• A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

  NCT07509892

  RecruitingInterventionalPhase 2Updated Jul 8, 2026
• A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

  NCT05959694

  Unknown statusInterventionalPhase 1Phase 2Updated Oct 23, 2023
• A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

  NCT05140824

  TerminatedInterventionalPhase 1Updated Apr 15, 2024
• TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment

  NCT02711813

  TerminatedInterventionalPhase 2Updated May 23, 2018
• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

  NCT03161483

  CompletedInterventionalPhase 2Updated Jun 15, 2023

ClinicalTrials.gov ID

NCT06859931

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

120Estimated

Last Update Posted

Mar 5, 2025Actual

Start Date

Mar 2025Estimated

Primary Completion Date

Dec 2026Estimated

Completion Date

Dec 2026Estimated

Official Title

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB3702 Tablets in Patients With Systemic Lupus Erythematosus

Brief Summary

TQB3702 is a selective kinase inhibitor. This is a Phase II clinical study aimed at evaluating the efficacy and safety of TQB3702 tablets in patients with systemic lupus erythematosus.

• Systemic Lupus Erythematosus

• TQB3702 Tablets
• TQB3702 Tablets+TQB3702 Placebo
• TQB3702 Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• The subjects voluntarily participate in the study and sign the informed consent;
• Male and female, ≥18 years old and ≤70 years old (subject to the date of signing the informed consent);
• The diagnosis meets the classification criteria of SLE established by the International Clinical Collaboration on Lupus Research (SLICC) in 2012 and has been in place for at least 6 months (Appendix 16), excluding drug-related lupus;
• Meet the Systemic lupus erythematosus disease activity index-2K score requirements
• Positive for one or more of the following antibodies: positive for anti-nuclear antibodies (ANA titers greater than or equal to 1:80 by immunofluorescence) and/or positive for anti-DSDNA antibodies and/or positive for anti-Smith(anti-SM);
• Subjects were receiving standard treatment for SLE and had received treatment for at least 3 months prior to randomization. Standard therapeutic doses of SLE were stable for at least 30 days and glucocorticoids were stable for at least 2 weeks prior to initial administration. The standard treatment for SLE may be corticosteroids, and/or antimalarial drugs, and/or immunosuppressants
• At the time of screening, if the subject is taking an angiotensin-converting enzyme inhibitor or an angiotensin-II receptor blocker or a non-steroidal anti-inflammatory drug (NSAID) orally, it must be at least 2 weeks since the pre-screening dose stabilized;
• Subjects must stop all opioids at least 1 week before the first dose;
• Fertile subjects must consent to and commit to using a medically accepted form of contraception throughout the study period and for at least 6 months after the final trial drug administration.

Exclusion Criteria:

• Subjects who are pregnant or lactating, or who plan to have a child in the 12 months prior to the first dosing.
• Severe lupus nephritis within 30 days prior to initial administration;
• Central nervous system diseases caused by SLE or not caused by SLE in the 12 months before the first dose;
• Current or past autoimmune diseases other than SLE
• There is an active and uncontrolled infection, or an infection that has recently required intravenous anti-infective therapy, or is currently being treated for any chronic infection
• Subjects whose chest radiology within 6 months prior to screening indicates active tuberculosis
• Have active hepatitis, or hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive + hepatitis B virus (HBV) DNA positive, or hepatitis C virus (HCV) RNA positive; Or a history of human immunodeficiency virus (HIV) infection, or a positive HIV serological result at screening; The specific antibody of Treponema pallidum was positive and the confirmatory test was positive. If HBV core antibody is positive but HBV-DNA is negative, HBV-DNA should be monitored once every 3 months.
• Herpes or shingles infection, or a history of disseminated/complicated shingles in the 12 weeks prior to screening;
• Cardiovascular and cerebrovascular abnormalities;
• Have a lung disease that the investigator determines is not suitable for participation in the study
• Subjects with a history or suspected demyelinating disease of the central nervous system;
• Subjects with a history of or suspected demyelinating disease of the central nervous system;
• Subjects with any type of active malignancy or with a history of malignancy;
• Have a history of vital organ transplantation or hematopoietic stem cell/bone marrow transplantation;
• The subject has any medical condition that may affect the absorption of oral medications (e.g., bariatric/obesity surgery, or the subject is unable to take oral medications;
• Previous use of specific drugs;
• Patients who underwent plasma replacement within 12 weeks prior to initial administration or treated with human immunoglobulin 4 weeks prior to initial administration;
• Cyclophosphamide had been used within 3 months before the first dose;
• Rituximab or any other B-cell depletion therapy within 6 months prior to initial administration;
• Use Beliuzumab, Taitacept, tumor necrosis factor (TNF) antagonists, or other biologics before initial administration unless the elution time is met, as specified in Appendix 17;
• Participants who have suffered a major trauma, fracture, or surgical procedure in the 4 weeks prior to screening, or who are expected to require major surgical procedures during the study period;
• Participants who received live attenuated vaccine within 28 days before the start of study treatment, inactivated vaccine within 7 days, or planned vaccination during the study period.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY

doczchen2023@126.com13956963042

13030300169@163.com13030300169

63886515@qq.com13733578758

2084334@qq.com17707393600

Ap2376@sohu.com13944579960

1315710223@qq.com13834547708

ltter.zjm@163.com15681932263

zce163163@163.com18087991755

13957741565@qq.com13957741565